Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mycology

Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program

M. A. Pfaller, D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S.-C. Chang, D. L. Gibbs, V. A. Newell, the Global Antifungal Surveillance Group
M. A. Pfaller
1University of Iowa College of Medicine, Iowa City, Iowa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael-pfaller@uiowa.edu
D. J. Diekema
1University of Iowa College of Medicine, Iowa City, Iowa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Mendez
2Hospital Militar Central, Bogotá, Columbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Kibbler
3Royal Free Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Erzsebet
4ANTSZ BAZ Megyei Intezete, Miscolc, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.-C. Chang
5National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. L. Gibbs
6Giles Scientific, Inc., Santa Barbara, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. A. Newell
6Giles Scientific, Inc., Santa Barbara, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00865-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • TABLE 1.

    Variation in frequency of Candida guilliermondii by geographic regiona

    RegionTotal no. of Candida species isolatesTotal no. (%) of C. guilliermondii isolates
    Asia-Pacific17,183190 (1.1)
    Europe41,187392 (1.0)
    Latin America11,280413 (3.7)
    North America6,11134 (0.6)
    Total75,7611,029 (1.4)
    • ↵ a Data were obtained from the ARTEMIS DISK Global Antifungal Surveillance Program, 2001 to 2003. Isolates represent all incident isolates from all sites of infection.

  • TABLE 2.

    Geographic variation in susceptibility of Candida guilliermondii to fluconazole and voriconazole

    RegionAntifungal agentNo. of isolates tested% of isolatesa
    SSDDR
    Asia-PacificFluconazole19077.414.77.9
    Voriconazole10587.62.99.5
    EuropeFluconazole39273.014.013.0
    Voriconazole22092.83.63.6
    Latin AmericaFluconazole41377.012.810.2
    Voriconazole27491.64.04.4
    North AmericaFluconazole3467.723.58.8
    Voriconazole3488.28.83.0
    TotalFluconazole1,02975.214.010.8
    Voriconazole63391.23.94.9
    • ↵ a All isolates were tested by the disk diffusion method performed in accordance with CLSI standard M44-A. S, susceptible, with zone diameters of ≥19 mm for fluconazole and ≥17 mm for voriconazole; SDD, susceptible-dose dependent, with zone diameters of 15 to 18 mm for fluconazole and 14 to 16 mm for voriconazole; R, resistant, with zone diameters of ≤14 mm for fluconazole and ≤13 mm for voriconazole.

  • TABLE 3.

    Susceptibility of Candida guilliermondii to fluconazole and voriconazole by clinical service

    Clinical service (total no. of isolates)aAntifungal agentNo. of isolates tested (%)b% of isolates from servicec% of isolates
    SSDDR
    Hematology-oncology (4,635)Fluconazole47 (4.6)1.078.76.414.9
    Voriconazole32 (5.1)96.93.1
    Medical (17,408)Fluconazole159 (15.4)0.979.913.26.9
    Voriconazole124 (19.6)93.53.23.2
    Surgical (5,126)Fluconazole51 (5.0)0.968.623.57.8
    Voriconazole47 (7.4)91.54.34.3
    Intensive care unit (10,052)Fluconazole67 (6.5)0.779.111.99.0
    Voriconazole55 (8.7)90.91.87.3
    Dermatology (1,457)Fluconazole158 (15.3)10.857.624.118.4
    Voriconazole121 (19.1)90.96.62.5
    Urology (649)Fluconazole14 (1.4)2.278.67.114.3
    Voriconazole6 (0.9)83.316.7
    Outpatient (6,414)Fluconazole47 (4.6)0.774.510.614.9
    Voriconazole25 (3.9)84.08.08.0
    Other, NOS (30,020)Fluconazole486 (47.2)1.679.211.59.3
    Voriconazole223 (35.2)90.13.26.7
    • ↵ a Total number of Candida isolates from each service.

    • ↵ b Percentage of all C. guilliermondii isolates tested.

    • ↵ c C. guilliermondii as a percentage of all isolates from that clinical service.

  • TABLE 4.

    Susceptibility of Candida guilliermondii to fluconazole and voriconazole by specimen type

    Specimen type/site (total no. of isolates)aAntifungal agentNo. of isolates tested (%)b% of isolates from sitec% of isolates
    SSDDR
    Blood (8,256)Fluconazole307 (29.8)3.785.09.15.9
    Voriconazole198 (31.3)93.41.55.1
    NSBF (3,155)Fluconazole36 (3.5)1.172.222.25.6
    Voriconazole30 (4.7)96.73.3
    Urine (9,722)Fluconazole78 (7.6)0.871.812.815.4
    Voriconazole51 (8.1)80.43.915.7
    Respiratory (20,274)Fluconazole136 (13.2)0.777.210.312.5
    Voriconazole72 (11.3)88.84.27.0
    Skin/soft tissue (4,986)Fluconazole127 (12.3)2.567.724.47.9
    Voriconazole103 (16.3)93.45.81.0
    Genital (15,831)Fluconazole44 (4.3)0.384.16.89.1
    Voriconazole20 (3.2)95.05.0
    Misc., NOS (13,537)Fluconazole301 (29.3)2.267.416.616.0
    Voriconazole159 (25.1)89.95.74.4
    • ↵ a Total number of Candida isolates from each specimen type.

    • ↵ b Percentage of all C. guilliermondii isolates tested.

    • ↵ c C. guilliermondii as a percentage of all isolates from that specimen type.

  • TABLE 5.

    In vitro activity of caspofungin against 132 bloodstream isolates of Candida guilliermondiia

    OrganismMIC (μg/ml)Cumulative % of isolates at MIC (μg/ml) of:
    Range50%b90%b0.120.250.51248
    C. guilliermondii 0.03->80.5121398195969696
    • ↵ a Isolates tested in RPMI 1640 broth with 24 h of incubation and a prominent reduction endpoint criterion (MIC-2).

    • ↵ b MIC encompassing 50% and 90% of isolates tested, respectively.

PreviousNext
Back to top
Download PDF
Citation Tools
Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program
M. A. Pfaller, D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S.-C. Chang, D. L. Gibbs, V. A. Newell, the Global Antifungal Surveillance Group
Journal of Clinical Microbiology Oct 2006, 44 (10) 3551-3556; DOI: 10.1128/JCM.00865-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program
M. A. Pfaller, D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S.-C. Chang, D. L. Gibbs, V. A. Newell, the Global Antifungal Surveillance Group
Journal of Clinical Microbiology Oct 2006, 44 (10) 3551-3556; DOI: 10.1128/JCM.00865-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Candida
candidiasis
Drug Resistance, Fungal
fluconazole

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X